SHAYNA R. SAROSIEK MD
Prescription History 1083840607
Internal Medicine - Hematology in Boston, MA
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SHAYNA R. SAROSIEK MD, an active Hematology specialist practicing in Boston, MA. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 322 documented patient claims. Among these therapy options, the most frequently utilized medication is Brukinsa, which accounts for 233 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2023)Rx (2023) | Avg Cost per FillCost / Fill | Vs. Other MA PrescribersVs. MA Avg |
|---|---|---|---|
| BrukinsaZanubrutinib | 233 | $13,189.43▼ below MA avg | ▲ More than typical |
About Brukinsa: This medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia). Show more ▾ Zanubrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. In 2023, this provider wrote 233 Medicare prescriptions for Brukinsa, about 6 times the volume of the typical Massachusetts prescriber of this medication (39). Medicare paid an average of $13,189.43 per fill, versus $13,620.04 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MA average for this medication. 233 30-Day Fills standardized to 30-day supplies 6,990 Days of Medication total across all patients in 2023 | |||
| EliquisApixaban | 18 | $588.25▼ below MA avg | ▼ Less than typical |
About Eliquis: Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. Show more ▾ With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood. In 2023, this provider wrote 18 Medicare prescriptions for Eliquis, about a quarter of the volume of the typical Massachusetts prescriber of this medication (77). Medicare paid an average of $588.25 per fill, versus $792.72 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MA average for this medication. 18 30-Day Fills standardized to 30-day supplies 540 Days of Medication total across all patients in 2023 | |||
| VenclextaVenetoclax | 17 | $15,067.02 | ▼ Less than typical |
About Venclexta: This medication is used to treat certain types of cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML). Show more ▾ Venetoclax is a drug that works by helping to slow or stop the growth of cancer cells. In 2023, this provider wrote 17 Medicare prescriptions for Venclexta, about 71% of the volume of the typical Massachusetts prescriber of this medication (24). Medicare paid an average of $15,067.02 per fill, versus $10,973.48 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 17 30-Day Fills standardized to 30-day supplies 496 Days of Medication total across all patients in 2023 | |||
| Entecavir | 16 | $67.05▼ below MA avg | ▼ Less than typical |
About Entecavir: See also Warning section. Show more ▾ Entecavir is used to treat long-term hepatitis B infection. Hepatitis B is an infection of the liver caused by the hepatitis B virus. Long-term infection can cause liver damage, rarely liver cancer, and liver failure. Entecavir helps to decrease the amount of hepatitis B virus in your body. It is unknown if this medication lowers your chance of getting liver cancer or liver damage. Entecavir is an antiviral that belongs to a class of drugs known as hepatitis B virus nucleoside reverse transcriptase inhibitors. Entecavir is not a cure for hepatitis B. It does not prevent the spread of the virus to others through sexual contact or blood/body fluid contamination (such as sharing used needles). In 2023, this provider wrote 16 Medicare prescriptions for Entecavir, about 67% of the volume of the typical Massachusetts prescriber of this medication (24). Medicare paid an average of $67.05 per fill, versus $485.09 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MA average for this medication. 22 30-Day Fills standardized to 30-day supplies 660 Days of Medication total across all patients in 2023 | |||
| ProcritEpoetin Alfa | 14 | $3,216.66 | ▼ Less than typical |
About Procrit: This medication is used to treat anemia (low red blood cell count) in people with long-term serious kidney disease (chronic kidney failure), people receiving zidovudine to treat HIV, and people receiving chemotherapy for some types of cancer (cancer that does Show more ▾ not involve the bone marrow or blood cells). It may also be used in anemic patients to reduce the need for blood transfusions before certain planned surgeries that have a high risk of blood loss (usually given with an anticoagulant/blood thinner medication such as warfarin to lower the risk of serious blood clots). Epoetin alfa works by signaling the bone marrow to make more red blood cells. This medication is very similar to the natural substance in your body (erythropoietin) that prevents anemia. This monograph is about the following epoetin alfa products: epoetin alfa and epoetin alfa-epbx. A recombinant glycosylated form of erythropoietin which stimulates the differentiation and proliferation of erythroid precursors. It is used for the treatment of ANEMIA associated with CHRONIC RENAL FAILURE in dialysis and predialysis patients. In 2023, this provider wrote 14 Medicare prescriptions for Procrit, about 61% of the volume of the typical Massachusetts prescriber of this medication (23). Medicare paid an average of $3,216.66 per fill, versus $1,195.62 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 14 30-Day Fills standardized to 30-day supplies 273 Days of Medication total across all patients in 2023 | |||
| ImbruvicaIbrutinib | 12 | $14,975.89 | ▼ Less than typical |
About Imbruvica: This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Show more ▾ Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system). In 2023, this provider wrote 12 Medicare prescriptions for Imbruvica, about a third of the volume of the typical Massachusetts prescriber of this medication (30). Medicare paid an average of $14,975.89 per fill, versus $14,871.47 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 12 30-Day Fills standardized to 30-day supplies 338 Days of Medication total across all patients in 2023 | |||
| Torsemide | 12 | $21.84▼ below MA avg | ▼ Less than typical |
About Torsemide: Torsemide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. Show more ▾ This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. This drug is also used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Torsemide is a water pill (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt. A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor (loop diuretic). It is used for the treatment of EDEMA associated with CONGESTIVE HEART FAILURE; CHRONIC RENAL INSUFFICIENCY; and LIVER DISEASES. It is also used for the management of HYPERTENSION. In 2023, this provider wrote 12 Medicare prescriptions for Torsemide, about a third of the volume of the typical Massachusetts prescriber of this medication (38). Medicare paid an average of $21.84 per fill, versus $25.17 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average MA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MA average for this medication. 12 30-Day Fills standardized to 30-day supplies 315 Days of Medication total across all patients in 2023 | |||
About this data. The prescription history for SHAYNA R. SAROSIEK MD is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2023, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Hematology prescribing approach at this Boston, MA practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average volume among MA prescribers of the same medication. Always confirm current medications and costs directly with the provider and your plan.
